Severe Uncontrolled Asthma Highlights
Key Points
- Tezspire is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation
- Tezspire helps in stopping inflammation at the source and has the potential to treat a broad population of severe asthmatic patients
Thymic stromal lymphopoietin (TSLP), which was primarily identified in 1994 as a cytokine produced by thymic stromal cells, a short-chain four α-helical bundle type I interleukin-2 (IL-2) family cytokine shares its homology with IL-7. It was observed to be quite similar to IL-25 and IL-33. Its ability to differentiate naïve CD4+ T lymphocytes in type 2 cells, produce IL-4, IL-5, and IL-13, and reduce the expression of interferon γ (IFN-γ) related to type 1 cells is well known. The expression of TSLP increases in the asthmatic airways and correlates with the expression of type 2-attracting chemokines and the severity of the disease.
In December 2021, AstraZeneca and Amgen’s Tezspire/tezepelumab got approval by the USA FDA as an add-on therapy for the treatment of patients affected with severe asthma. Tezspire acts at the top of the inflammatory cascade by targeting TSLP and was approved following a Priority Review by the USA FDA and based on the results from the PATHFINDER clinical trial program. The application included results from the pivotal NAVIGATOR Phase III trial in which Tezspire demonstrated dominance across every primary and key secondary endpoint in patients with severe asthma compared with placebo while adding to standard therapy.
Furthermore, it is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase II and III clinical trials which included a broad population of severe asthma patients irrespective of key biomarkers, including blood eosinophil counts allergic status, and fractional exhaled nitric oxide (FeNO). It is the only biologic approved for severe asthma with no phenotype (e.g. eosinophilic or allergic) or biomarker limitation within its approved label.
“The essential function of TSLP in immunological homeostasis and modulating inflammatory responses at mucosal barriers may explain why tezepelumab is so effective in treating severe uncontrolled asthma”
In May 2022, the data presented at the American Thoracic Society (ATS) International Conference 2022 showed based on a study that patients with severe, uncontrolled asthma demonstrated a higher proportion of substantial clinical responses to tezepelumab. The study uses data from the completed phase III, double-blind, placebo-controlled NAVIGATOR trial to conduct an on-treatment analysis of responses to tezepelumab (NCT03347279).
In the analysis, 51% of the patients received tezepelumab vs. placebo. Across response criteria, the proportion of responders was higher in the tezepelumab as compared with the placebo group for exacerbation reduction i.e. 85.4% vs. 67.5%; Asthma Control Questionnaire (ACQ)-6 total score (86.9% vs. 76.6%); an improvement from baseline pre-bronchodilator forced expiratory volume in one second (FEV1) i.e. 60.3% vs. 49.9%; and in Clinical Global Impression of Change (CGI-C) score (81.5% vs. 67.7%). The proportion of complete responders (those who achieved significant improvement on all measures) in the tezepelumab group as compared with the placebo cohort was double.
New novel approaches that are capable of blocking TSLP such as fully human single-chain fragment variables against TSLP, bi-functional drugs that combine anti-IL-13 monoclonal antibodies with an anti-TSLP mAb, a fusion protein consisting of the ectodomains of TSLPR and IL-7Ra that extend into the extracellular space which is also known as a TSLP-trap, fragments capable of upsetting the TSLP/TSLPR complex are also expected to enter the market. Some assets are under preclinical investigation e.g. Zweimab (monovalent bispecific) and Doppelmab (bivalent bispecific) which are novel highly potent bispecific anti-TSLP/IL13 antibodies. It has also been observed that Zweimab and Doppelmab have a stronger affinity to the human targets compared to parental antibody formats.
Both TSLP and IL-13 have arisen as important players in cellular signaling in asthma which is categorized by Th2 inflammation. According to DelveInsights’s analysis of the Severe Asthma market, Tezespire is expected to reach sales close to $2Bn for the 7 major markets by 2032. So far biological treatments appear to be a more preferred long-term treatment against type 2 inflammation in severe asthma to reduce OCS exposure. Although there have been no head-to-head comparisons of biologic medicines for asthma to date, the findings of these studies imply that tezepelumab is as effective as other treatments at reducing exacerbations.
For more detailed analysis, visit the Severe Asthma market.
To know more on Severe Uncontrolled Asthma Highlights, visit @ Severe Asthma Market Highlights.
Accordingly, KOSA Acupuncture treats the lungs and liver at the same time and if the patient has other conditions all of them are treated at once as well.
Acupuncture in Gaithersburg Maryland - Usually, the asthma patients don’t have to use the nebulizer or inhaler with no more than five sessions.
Acupuncture for Asthma - When your asthma symptoms become worse than usual, it’s called an asthma attack.
Severe asthma attacks may require emergency care, and they can be fatal.
Asthma can sometimes be stressful and challenging.
But it does not have to be a limiting condition.
We have selected the best asthma blogs that include useful tips and suggestions to help you keep your asthma symptoms under control.allergic asthma and covid-19 allergic asthma and covid-19 vaccine asthma after covid-19 recovery asthma and copd in hospitalized covid-19 patients asthma and covid 19 google scholar asthma and covid 19 how to tell the difference asthma and covid 19 vaccine uk asthma and covid-19 latest research asthma diagnosis test asthma diseasehttps://usamedilife.com/product/aerocort-forte-rotacaps/
In a pinch and need to know how to get asthma relief without an inhaler.
Asthma Attack No Inhaler: What to Do 1.Sit Upright 2.
Identify the trigger3.Drink a Hot, Caffeinated Beverage 4.
Do not use methadone if you are allergic to it, or if you have: breathing problems or severe asthmaa blockage in your stomach or intestines To make sure methadone is safe for you, tell your doctor if you have ever had: breathing problems, sleep apnea liver or kidney disease brain tumor, a head injury, or seizuresheart problems, long QT syndrome (in you or a family member)alcohol or drug addiction, or mental illnessurination problemsproblems with your gallbladder, pancreas, or thyroid Methadone can cause a fatal heart rhythm disorder.
If you have a headache with chest pain, severe dizziness, or fast or pounding heartbeats, call your doctor right away.
Your doctor may check your heart function during treatment.
If you use opioid medications while pregnant, your baby may become dependent on the drug.
This can cause fatal withdrawal symptoms in the baby after birth.
Babies born dependent on opioids may require medical care for several weeks.
The Global Asthma & COPD Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027 gives an evaluation of the market developments based on historical studies and comprehensive research respectively.
The market segments are also provided with an in-depth outlook of the competitive landscape and a listing of the profiled key players.The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved.
The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.
The report classifies the market into different segments.
These segments are studied in detail incorporating the market estimates and forecasts at regional and country level.
The segment analysis is useful in understanding the growth areas and probable opportunities of the market.Final Report will cover the COVID-19 Impact and Recovery on this industry.Browse the complete Global Asthma & COPD Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027 @ https://www.decisiondatabases.com/ip/29217-asthma-copd-market-report The report also covers the complete competitive landscape of the global Asthma & COPD market with company profiles of key players such as: GSKNovartisMerckAbbottBoehringer IngelheimAstraZenecaRocheTevaVecturaPfizerMylanAllerganCiplaAkornThe detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.SEGMENTATIONS IN THE REPORT:By ProductAnti-inflammatory DrugsBronchodilator MonotherapyCombination DrugsBy End Users/ApplicationsHospital PharmaciesPrivate ClinicsDrug StoresRetail PharmaciesE-CommerceBy Geography:North America (NA) – US, Canada, and MexicoEurope (EU) – UK, Germany, France, Italy, Russia, Spain & Rest of EuropeAsia-Pacific (APAC) – China, India, Japan, South Korea, Australia & Rest of APACLatin America (LA) – Brazil, Argentina, Peru, Chile & Rest of Latin AmericaMiddle East and Africa (MEA) – Saudi Arabia, UAE, Israel, South AfricaDownload Free Sample Report of Global Asthma & COPD Market @ https://www.decisiondatabases.com/contact/download-sample-29217The Global Asthma & COPD Market has been exhibited in detail in the following chapters –Chapter 1 Batch Coding Machines Market PrefaceChapter 1 Asthma & COPD Market PrefaceChapter 2 Executive SummaryChapter 3 Asthma & COPD Industry AnalysisChapter 4 Asthma & COPD Market Value Chain AnalysisChapter 5 Asthma & COPD Market Analysis By ProductChapter 6 Asthma & COPD Market Analysis By End Users/ApplicationsChapter 7 Asthma & COPD Market Analysis By GeographyChapter 8 Competitive Landscape Of Asthma & COPD CompaniesChapter 9 Company Profiles Of Asthma & COPD IndustryPurchase the complete Global Asthma & COPD Market Research Report @ https://www.decisiondatabases.com/contact/buy-now-29217Other Reports by DecisionDatabases.com:Global Asthma Spacers Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2027Global Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Research Report – Industry Analysis, Size, Share, Growth, Trends and Forecast Till 2026About-Us:DecisionDatabases.com is a global business research reports provider, enriching decision makers and strategists with qualitative statistics.
